Mirtazapine-moclobemide

From Psychiatrienet
Revision as of 14:47, 7 October 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from mirtazapine to moclobemide.[1] [2]

Nietinrijdenbord.png Stop mirtazapine
  • Before day 1: Gradually reduce dosage of mirtazapine to a maximum of 30 mg/day, when this dosage is > 30 mg/day.
  • Day 1: Reduce dosage of mirtazapine to 15 mg/day.
  • Day 8: Stop administration of mirtazapine.
Eenrichtingbord.png Start moclobemide
  • Day 8-14: A wash-out period of one week is necessary.
  • Day 15: Start administration of moclobemide 150 mg/day
  • Day 23: Increase moclobemide dosage to 300 mg/day
Infobord.png More information
  • Occurrence of serotonin syndrome is not very likely. For safety reasons a wash-out period (of one week) is considered.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.